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Background: The basal pattern of p53 expression, defined as its immunoreactivity confined to the basal half of the
glands, is associated with early neoplastic lesions in ulcerative colitis (UC). However, their clinical utility of this
finding is limited by the use of “visual estimation” (approximate immunoreactivity on the basis of scanning the
stained slide, without formal counting). This study was designed to analyze the basal pattern of p53 using
computer-assisted cytometry and to identify the optimal cutoff value for discriminating between UC-associated
early-stage neoplasia and regenerative atypia.
Methods: The specimens were obtained from eight UC patients undergoing colectomy and were classified
according to the criteria by the Research Committee of Inflammatory Bowel Disease of the Ministry of Health and
Welfare in Japan. Patients with classes UC-IIa (indefinite for dysplasia, probably regenerative), UC-IIb (indefinite for
dysplasia, probably dysplastic), and UC-III (definitive dysplasia) were enrolled in the study. Based on the percentage
of immunoreactive cells in the basal half of the crypt with visual estimation, basal positivity of p53 was classified
into three categories: grade 1 (1 - 9%), grade 2 (10 - 19%), and grade 3 (≥20%). Next, crypts classified as grade 3 by
visual estimation were analyzed by computer-assisted image analysis.
Results: Using visual estimation, grade-3 p53 basal positivity was observed in 46.0% of UC-IIa crypts (128 of 278),
61.9% of UC-IIb crypts (39 of 63), and 94.2% of UC-III crypts (81 of 86). Using image analysis, the median p53 basal
positivities were 30.3% in UC-IIa, 52.3% in UC-IIb, and 65.4% in UC-III (P ≤0.002). A receiver operating characteristics
curve was generated to determine the method’s diagnostic utility in differentiating UC-IIa from UC-III. In this cohort,
the sensitivity was 0.78; the specificity was 0.98; the negative predictive value was 87.4%; the positive predictive
value was 95.5%, and the accuracy was 90.2% with a cutoff value for p53 basal positivity of 46.1%.
Conclusions: Our findings indicate that assessing p53 basal positivity by image analysis with an optimal threshold
represents an alternative to visual estimation for the accurate diagnosis of UC-associated early-stage neoplasia.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/3588120501252608
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There is an increasing incidence of ulcerative colitis (UC)-
associated neoplasia among patients with long-standing
and extensive disease [1,2]. However, UC-associated early-
stage neoplasia is not easily detected by endoscopy, because
those lesions are sometimes missed among the inflamed
epithelium [3]. In addition, the histological diagnosis of
early-stage neoplasia, which often has unremarkable cyto-
logical alterations [4], is difficult due to the recurrent and
persistent inflammatory changes associated with UC. Other
difficulties in early detection result from specific his-
tological features of UC-associated early-stage neoplasia,
which can involve only one part of the crypt or a few crypts
in the inflamed epithelium [4]. Consequently, it is difficult
to distinguish UC-associated early-stage neoplasia from
regenerative atypia in biopsy specimens stained with
hematoxylin and eosin (H&E) [5]. Moreover, there is a
concerning degree of inter- and intra-observer vari-
ation in the diagnosis of UC-associated early-stage neo-
plasia and regenerative atypia among gastrointestinal
pathologists [5].
Mutations in the p53 gene represent an early event in
the development of UC-associated neoplasia [6-8]. Immu-
nohistochemical analysis of the p53 protein is a useful
method for detecting UC-associated early-stage neoplasia,
since there is a concordance between p53 gene mutation
and its expression [7-9]. Immunohistochemstry for p53
was positive in 11 - 75% of low-grade dysplasia and 45 -
83% of high-grade dysplasia but was negative in regene-
rative epithelium in UC [9-12]. Accordingly, Wong et al.
reported intense p53 staining in 14% of low-grade dyspla-
sia and 57% of high-grade dysplasia but not in regenerative
epithelium with atypia in UC [13]. They reported that re-
striction of p53 expression to the basal two-thirds of the
crypt excluded a diagnosis of UC-associated high-grade
dysplasia. Noffsinger et al. reported that p53 basal expres-
sion was associated with p53 mutation and represented an
early neoplastic change in a subgroup of UC patients [7].
Moreover, UC-associated early-stage neoplasia had a sig-
nificantly higher proportion and a different pattern of p53
immunoreactivity than sporadic adenoma [11,14]. The
immunoreactivity in sporadic adenomas had a scattered
or sporadic pattern of p53 expression [11], while UC-
associated early-stage neoplasia exhibited a “bottom-up”
pattern [7,13]. However, the utility of these reports is lim-
ited by the “visual estimation” of basal pattern of p53 im-
munoreactivity, where the approximate immunoreactivity
was determined by scanning the stained slide without
formal counting [15]. Recently, the emergence of digital
pathology and software analysis of data has led to the de-
velopment of a reliable and reproducible digital analytical
technique for Ki-67 immunoreactivity [15,16].
The aim of this study was to analyze the basal pattern of
p53 immunoreactivity using computer-assisted cytometryand to identify the optimal cutoff value for basal positivity
of p53 in order to discriminate between UC-associated
early-stage neoplasia and regenerative atypia.
Methods
Patients and materials
Tissue samples were obtained from eight UC patients (five
males and three females; mean/median age, 46.0/47.5 years,
range, 21–67 years; mean/median duration of disease,
21.3/15.0 years, range 6–43 years) who underwent total
colectomy for UC-associated neoplasia at Tokyo Women’s
Medical University and Dokkyo Medical University School
of Medicine between January 2010 and December 2011.
Colectomy specimens were fixed in 10% formalin and
cut to a width of 5 mm and then embedded in paraffin,
sectioned, and stained with H&E. The specimens were
histologically evaluated by three experienced gastrointes-
tinal pathologists (S.K., T.F., H.M.) and were classified
according to the classification proposed by the Research
Committee of Inflammatory Bowel Disease of the Minis-
try of Health and Welfare in Japan [17]. Inter-observer
variations were resolved by reevaluation and discussion
to reach consensus. Patients classified as having UC-IIa
(indefinite for dysplasia, probably regenerative), UC-IIb
(indefinite for dysplasia, probably dysplastic), and UC-III
(low or high-grade dysplasia) were enrolled in this study.
The Ethics Committee of Dokkyo Medical University
School of Medicine approved all protocols, and informed
consent for tissue procurement was obtained from all
patients. Samples used in this study were surgically
resected for treatment, not for research purposes. Par-
ticipation in the present study did not increase medical
disadvantage or risk to patients.
Immunohistochemistry for p53
Briefly, 4-μm-thick serial sections were placed on
silane-coated slides, deparaffinized, rehydrated, and pre-
treated with 0.3% hydrogen peroxidase in methanol at
room temperature to quench endogenous peroxidase ac-
tivity. The sections were then placed in 0.01 M citrate buf-
fer (pH 6.0) and treated by microwave heating (MI-77,
Azumaya, Tokyo, Japan; 400 W, 95°C) to facilitate antigen
retrieval. The sections were incubated with 1% bovine
serum albumin in phosphate-buffered saline and then
with a monoclonal anti-human p53 antibody (DO-7;
1:50 dilution; DAKO, Glostrub, Denmark). Immunohis-
tochemical staining was performed with EnVisionTM +
Kits (DAKO). Finally, the sections were incubated with
3,3′-diaminobenzidine and counterstained lightly with
Carazzi’s hematoxylin.
Visual estimation of p53 expression
Neoplastic lesions in each p53-immunostained slide
were confirmed using the corresponding H&E-stained
Table 1 Grade of p53 basal positivity in the crypts in




UC-IIa (%) UC-IIb (%) UC-III (%)
(n = 278) (n = 63) (n = 86)
Grade 1 74 (26.6) 16 (25.4) 2 (2.3)
Grade 2 76 (27.3) 8 (12.7) 3 (3.5)
Grade 3 128 (46.1) 39 (61.9) 81 (94.2)
Figure 1 p53 basal positivity in grade 3 UC-IIa, IIb, and III.
Median values of the p53 basal positivities were 30.3% in UC-IIa,
52.3% in UC-IIb, and 65.4% in UC-III with statistically significant
differences among the all categories. Middle lines, median; boxes,
25th to 75th percentiles; upper limit, 95th percentile; lower limit,
10th percentile; †, P < 0.001; ‡, P = 0.002.
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p53 expression, which was characterized by p53 immu-
noreactivity in the basal half of the crypts, as described
by Noffisinger et al. [7]. In addition, the unique basal
pattern of p53 expression was classified into three categor-
ies according to the percentage of immunoreactive cells in
the basal half of the crypt as follows: grade 1 (1 - 9%);
grade 2 (10 - 19%), and grade 3 (≥20%). Immunohisto-
chemical images were imported into a PowerPoint presen-
tation and evaluated by two independent researchers (T.F.
and S.K.), who estimated the grade of p53 immunoreactiv-
ity based on their inspection of the images without
using computer-assisted image analysis (‘visual estimation’).
Inter-observer disagreements were resolved by reevaluation
and discussion to a reach consensus.
Analysis of p53 expression using computer-assisted
cytometry
Crypts classified as grade 3 by visual estimation were
analyzed using the computer-assisted cytometry with
WinROOF image-processing software (Mitani Corp.,
Tokyo, Japan). The glands subjected to image analysis
were continuously visible from the bottom of the glands
to the surface epithelium. The manual counting func-
tion of the image analysis was utilized, and p53-positive
cells in the basal half of the crypts were counted under
high-power magnification (at 400X) using a touch pen
by introducing a liquid crystal touch panel. The values
were expressed as the percentage of p53-positive cells
relative to the total number of crypt cells in the basal
half of the glands.
Statistical analysis
Continuous data were analyzed with the Mann–Whitney
U-test using Stat Flex Version 6.0 (Artec Co. Ltd., Osaka,
Japan). A P-value < 0.05 was considered statistically signifi-
cant. A receiver operating characteristics (ROC) curve was
generated with R Version 3.0.1 statistical software.
Results
A total of 1,039 crypts (a total of 103 lesions) consisting of
626 UC-IIa crypts (total 40 lesions; Case #1, 13 lesions;
Case #3, 1 lesion; Case #4, 1 lesion; Case #7, 12 lesions;
Case #8, 13 lesions), 256 UC-IIb crypts (40 lesions; Case
#1, 10 lesions; Case #2, 6 lesions; Case #3, 10 lesions; Case
#4, 6 lesions; Case #5, 4 lesions; Case #6, 4 lesions), and
157 UC-III crypts (23 lesions; Case #1, 7 lesions; Case #2,
9 lesions; Case #3, 3 lesions; Case #5: 3 lesions; Case #6, 1
lesion) were examined by visual estimation.
In first visual estimation, 278 out of 626 crypts (44.4%;
captured for 4 cases) in UC-IIa, 63 of 256 crypts (24.6%;
captured for 5 cases) in UC-IIb, and 86 of 157 crypts
(54.8%; captured for 4 cases) in UC-III revealed basal posi-
tivity for p53. Grade-3 p53 basal positivity was observed in128 of 278 crypts (46.0%) in UC-IIa, 39 of 63 crypts
(61.9%) in UC-IIb, and 81 of 86 crypts (94.2%) in UC-III
(Table 1).
For samples with grade-3 p53 basal positivity by quali-
tative estimate, computer-assisted cytometry was per-
formed using the WinROOF image-processing software.
In this analysis, median p53 basal positivities were 30.3%
(25–75 percentile: 25.6 - 37.6%) in UC-IIa, 52.3% (33.3 -
64.7%) in UC-IIb, and 65.4% (47.2 - 80.6%) in UC-III.
There were statistically significant differences between
IIa and IIb (P < 0.001), IIa and III (P < 0.001), and IIb
and III (P = 0.002) (Figure 1). Basal positivity of p53 in
representative cases of UC-IIa, IIb, and III lesions are il-
lustrated in Figure 2.
We generated the ROC curve in order to determine our
ability to differentiate between UC-IIb and UC-III, but the
sensitivity and negative predictive value and accuracy were
low (area under the curve [AUC], 0.678; 95% confidence
interval [CI], 55.82 - 63.18; P = 0.002; sensitivity, 0.42; spe-
cificity, 0.872; negative predictive value, 42.0%; positive
predictive value, 87.2%; accuracy, 56.7%). We subsequently
determined the ability to differentiate between UC-IIa and
UC-III by the ROC curve (Figure 3). The AUC was 0.928
(95% CI, 41.48 - 47.11; P < 0.001); the sensitivity was 0.78;
the specificity was 0.98: the negative predictive value was
Figure 2 Basal positivity of p53 in representative cases of UC-IIa, IIb, and III. (A) UC-IIa showing mild glandular distortion with slight nuclear
enlargement and hyperchromatism at the bottom of crypts. There is no nuclear stratification or mucin depletion. Moderate small round cell
infiltration with crypt abscess is present in the lamina mucosae (H&E, original magnification × 10). (B) Weak intensity of p53 staining is restricted
to the lower third of the crypts (serial sections of ‘A’; immunoperoxidase, original magnification × 10). (C) UC-IIb demonstrating hyperchromatic
and enlarged nuclei with slight stratification and occasional goblet cell depletion in the lower half of the crypts. Mild to moderate inflammation
is seen in the background mucosa (H&E, original magnification × 10). (D) p53 positivity is limited to the lower half of the crypts (serial section of
‘C’; immunoperoxidase, original magnification × 10). (E) UC-III shows marked hyperchromatic and stratified nuclei with some variation in size and
shape from the bottom of the crypt to the surface epithelium. Marked goblet cell depletion with mild inflammation is present in the mucosa
(H&E, original magnification × 10). (F) Strong p53 expression is identified in the lower two thirds of the crypts (serial section of ‘E’; immunoperoxidase,
original magnification × 10).
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curacy was 90.2% with a cutoff value of 46.1% for p53
basal positivity. Using this threshold, 2.3% of UC-IIa crypts
(3 of 128) and 61.5% of UC-IIb crypts (24 of 39) corre-
sponded to UC-III, whereas 22.2% of UC-III crypts (18 of
81) were excluded from being UC-III (Table 2).
Discussion
In the present study, we investigated the basal pattern of
p53 immunoreactivity in UC-III (definite dysplasia) and
UC-II (indefinite for dysplasia) crypts using computer-
assisted cytometry and determined the optimal cutoff
value for basal positivity of p53 for discriminating be-
tween the two categories. By visual estimation, Grade-3p53 basal positivity was observed in 46.0% of UC-IIa
crypts (indefinite for dysplasia, probably regenerative),
61.9% of UC-IIb crypts (indefinite for dysplasia, probably
dysplastic), and 94.2% of UC-III crypts. Our data are
consistent with the previously published hypothesis that
the basal pattern of p53 expression is not a specific sign
of dysplasia (UC-III); rather, this pattern was observed in
5 - 64% of regenerative mucosa and 13 - 33% of samples
indefinite for dysplasia [7,13].
There is significant discordance between visual estima-
tion and digital image analysis for Ki-67 immunoreactivity
[15]. Thus, we performed computer-assisted cytometrical
analysis using the WinRooF image-processing software,
which we developed in our previous study on Ki-67
Figure 3 ROC curve illustrating the ability to differentiate between
UC IIa and UC-III. ROC curve illustrating the high diagnostic ability with
a cutoff value of 46.1% for p53 basal positivity in the differentiation of
UC-III vs. UC-IIa, AUC = 0.928 (95% CI, 41.48 - 47.11; P< 0.001).
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visual estimation. We could exclude non-neoplastic (dys-
plastic) cells that occasionally display nonspecific positivity
for p53, such as lymphocytes or histiocytes, using a touch
pen by introducing a touch panel. Using this analysis, we
identified that p53 basal positivity was significantly higher
in UC-III crypts (median value, 65.4%) than in UC-IIb
crypts (52.3%) or UC-IIa crypts (30.3%). However, the
ROC curve indicated a low sensitivity (0.42) and negative
predictive value (42.0%) in differentiating between UC-III
and UC-IIb. Based on this result, we considered the possi-
bility that some of the UC-IIb crypts might be included in
the UC-III category. Indeed, 80% of UC-IIb crypts har-
bored p53 mutations [8].
Colectomy is often indicated in patients with a diag-
nosis of UC-III, whereas those with UC-IIa should
undergo repeat surveillance colonoscopy within a short
interval [2], but there is poor inter-observer agreement
for the two categories [5]. In this line, Matalka et al. de-
veloped an automated intelligent system to quantita-
tively assess inflammatory bowel system, which proved
to be reliable and minimizes inter- and intraobserver
variability [18]. In our ROC analysis for UC-III and UC-
IIa showing p53 basal positivity, the sensitivity (0.78)
and negative predictive value (87.4%) were improved
when the cutoff value was 46.1%. At this threshold, onlyTable 2 Frequency of UC-IIa, IIb, and III based on a new




UC-IIa (%) UC-IIb (%)% UC-III (%)
(n = 128) (n = 39) (n = 81)
20.0 - 46.0 125 (97.7) 15 (38.5) 18 (22.2)
>46.1 3 (2.3) 24 (61.5) 63 (77.8)2.3% of UC-IIa, but 61.5% of UC-IIb crypts were classi-
fied as UC-III.
A major goal in screening for definitive dysplasia is min-
imizing the false negative rate; therefore, we identified a
threshold of p53 basal positivity (i.e., > 40%) at which 17.2%
of UC-IIa crypts were interpreted as UC-III, and only
13.6% of UC-III crypts were missed from definitive dyspla-
sia. This indicates moderate-to-high sensitivity (86.4%) and
specificity (82.8%). These values are consistent with the
finding that 20% of UC-IIa crypts and 92% of UC-III crypts
harbored p53 mutations [8]. When p53 basal positivity is
above this threshold, even if the biopsy diagnosis is mor-
phologically indefinite for early-stage neoplasia in H&E
stained biopsy specimens, we recommend genetic analysis
for p53 or appropriate treatment, such as endoscopic or
surgical resection.Conclusions
Our present findings suggest that using computer-
assisted cytometrical analysis of p53 basal positivity with
an optimal threshold (standardization) represents an al-
ternative to visual estimation as an accurate tool for de-
tecting UC-associated early-stage neoplasia. The choice
of an appropriate therapeutic strategy may be informed
by using p53 basal positivity in biopsy samples in UC
patients.
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